TRIBE Trial: First-Line Treatment of mCRC
Published Online: Sunday, September 29, 2013
For High-Definition, ClickModerator, John L. Marshall, MD, introduces an in-depth panel discussion focused on the treatment of patients with metastatic colorectal cancer (mCRC). The exchange includes expert perspectives from a broad array of specialists, including Tanios Bekaii-Saab, MD, Fadi Braiteh, MD, CPI, Axel Grothey, MD, and Alan P. Venook, MD.
The conversation begins with a discussion of the recent phase III TRIBE trial, which was presented at the 2013 ASCO Annual Meeting. In this trial, FOLFOXIRI plus bevacizumab was compared to FOLFIRI plus bevacizumab as a first-line treatment for patients with mCRC. The primary endpoint of the trial was progression-free survival (PFS), although overall survival (OS) was also assessed, explains Axel Grothey, MD.
In total, 508 patients were enrolled in the trial. As expected, additional toxicity was observed with the FOLFOXIRI regimen; however, the levels of adverse events were tolerable, explains Grothey. In terms of efficacy, response rate was 64% compared to 53% for FOLFOXIRI and FOLFIRI, respectively. Furthermore, Grothey adds, the median PFS was 9.5 months with FOLFIRI versus 11.9 months with FOLFOXIRI (HR = 0.72).
Most impressively, Grothey believes, the median OS benefit for FOLFOXIRI plus bevacizumab was 31.0 months compared with 25.8 months in the FOLFIRI plus bevacizumab group (HR = 0.79, P = 0.054). At this point, the OS results are not statistically significant but will continue to be followed as the data matures. There were a few adjustments to the dosing for the FOFOXIRI regimen, notes Grothey. In this regimen, irinotecan was delivered at 180 mg/m2 ever 2 weeks compared to 165 mg/m2 with FOLFIRI.
A leading concern for the FOLFOXIRI plus bevacizumab regimen is that it deploys all effective therapies in the first-line setting leaving few new choices for second-line treatment, suggests Alan P. Venook, MD. To address this concern, the TRIBE trial administered the upfront regimen for 12 cycles (6 months) followed by 5-fluorouracil plus bevacizumab until progression. Following this approach, it may be acceptable to reintroduce irinotecan and oxaliplatin in the second-line setting, Grothey believes.
View More From This Discussion
Tanios Bekaii-Saab, MDSection Chief, Gastrointestinal Oncology Chair, OSUCCC Gastrointestinal Disease Research Group Associate Professor of Medicine and Pharmacology The Ohio State University – James Cancer Hospital
Fadi Braiteh, MD, CPIMedical Oncology, Director, Phase I Translational Oncology Program (TOP) and GI Malignancies USON Research & UCLA/TRIO-US Network Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Axel Grothey, MDProfessor of Oncology and Consultant
Division of Medical Oncology
Department of Oncology, Mayo Clinic
Alan P. Venook, MDThe Madden Family Distinguished Professor of Medical Oncology and Translational Research, University of California, San Francisco San Francisco, California
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.